Your browser doesn't support javascript.
loading
miRNAs can be generally associated with human pathologies as exemplified for miR-144.
Keller, Andreas; Leidinger, Petra; Vogel, Britta; Backes, Christina; ElSharawy, Abdou; Galata, Valentina; Mueller, Sabine C; Marquart, Sabine; Schrauder, Michael G; Strick, Reiner; Bauer, Andrea; Wischhusen, Jörg; Beier, Markus; Kohlhaas, Jochen; Katus, Hugo A; Hoheisel, Jörg; Franke, Andre; Meder, Benjamin; Meese, Eckart.
Afiliação
  • Keller A; Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany. ack@bioinf.uni-sb.de.
  • Leidinger P; Institute of Human Genetics, Saarland University, Homburg, Germany. p.leidinger@mx.uni-saarland.de.
  • Vogel B; Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany. britta.vogel@med.uni-heidelberg.de.
  • Backes C; Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany. c.backes@mx.uni-saarland.de.
  • ElSharawy A; Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Kiel, Germany. a.sharawy@ikmb.uni-kiel.de.
  • Galata V; Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany. valentina.galata@gmail.com.
  • Mueller SC; Chair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany. sabine.mueller@uniklinikum-saarland.de.
  • Marquart S; Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany. sabine.marquart@med.uni-heidelberg.de.
  • Schrauder MG; Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. michael.schrauder@uk-erlangen.de.
  • Strick R; Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. reiner.strick@uk-erlangen.de.
  • Bauer A; German Cancer Research Center, Heidelberg, Germany. andrea.bauer@dkfz.de.
  • Wischhusen J; University Hospital Würzburg, Würzburg, Germany. wischhusen_J@ukw.de.
  • Beier M; Comprehensive Biomarker Center, Heidelberg, Germany. markus.beier@cbioc.com.
  • Kohlhaas J; Comprehensive Biomarker Center, Heidelberg, Germany. jochen.kohlhaas@cbioc.com.
  • Katus HA; Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany. hugo.katus@med.uni-heidelberg.de.
  • Hoheisel J; German Center for Cardiovascular Research - DZHK, Germany, Heidelberg. hugo.katus@med.uni-heidelberg.de.
  • Franke A; German Cancer Research Center, Heidelberg, Germany. j.hoheisel@dkfz.de.
  • Meder B; Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Kiel, Germany. a.franke@ikmb.uni-kiel.de.
  • Meese E; Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany. benjamin.meder@med.uni-heidelberg.de.
BMC Med ; 12: 224, 2014 Dec 03.
Article em En | MEDLINE | ID: mdl-25465851
ABSTRACT

BACKGROUND:

miRNA profiles are promising biomarker candidates for a manifold of human pathologies, opening new avenues for diagnosis and prognosis. Beyond studies that describe miRNAs frequently as markers for specific traits, we asked whether a general pattern for miRNAs across many diseases exists.

METHODS:

We evaluated genome-wide circulating profiles of 1,049 patients suffering from 19 different cancer and non-cancer diseases as well as unaffected controls. The results were validated on 319 individuals using qRT-PCR.

RESULTS:

We discovered 34 miRNAs with strong disease association. Among those, we found substantially decreased levels of hsa-miR-144* and hsa-miR-20b with AUC of 0.751 (95% CI 0.703-0.799), respectively. We also discovered a set of miRNAs, including hsa-miR-155*, as rather stable markers, offering reasonable control miRNAs for future studies. The strong downregulation of hsa-miR-144* and the less variable pattern of hsa-miR-155* has been validated in a cohort of 319 samples in three different centers. Here, breast cancer as an additional disease phenotype not included in the screening phase has been included as the 20th trait.

CONCLUSIONS:

Our study on 1,368 patients including 1,049 genome-wide miRNA profiles and 319 qRT-PCR validations further underscores the high potential of specific blood-borne miRNA patterns as molecular biomarkers. Importantly, we highlight 34 miRNAs that are generally dysregulated in human pathologies. Although these markers are not specific to certain diseases they may add to the diagnosis in combination with other markers, building a specific signature. Besides these dysregulated miRNAs, we propose a set of constant miRNAs that may be used as control markers.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / MicroRNAs Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / MicroRNAs Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Alemanha